Expert Highlights Immunotherapy Advances in Lung Cancer Treatment Landscape
David M. Waterhouse, MD, MPH, shares advice with community oncologists treating patients with lung cancer.
David M. Waterhouse, MD, MPH, medical oncologist and hematologist, OHC (Oncology Hematology Care) and The US Oncology Network, shares advice with community oncologists treating patients with lung cancer.
The first thing to do is make sure every patient is tested for actionable biomarkers, says Waterhouse. Frontline immunotherapy is available for patients with PD-L1 greater than 50%. In addition, the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) can be used to treat any patient with a PD-L1 of 1% or higher, according to Waterhouse. This provide a chemotherapy-free treatment option for the frontline setting, which marks an exciting advance that Waterhouse says no one would have predicted just a few years ago.
It is important to wait for testing before treatment in patients with lung cancer, although there will be some patients that require treatment right away, but that is not the majority, Waterhouse says. Physicians must remind their patients of why it is in their best interest to wait.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
